These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 25223394)

  • 1. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.
    Ternant D; Ducourau E; Fuzibet P; Vignault C; Watier H; Lequerré T; Le Loët X; Vittecoq O; Goupille P; Mulleman D; Paintaud G
    Br J Clin Pharmacol; 2015 Feb; 79(2):286-97. PubMed ID: 25223394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate.
    Paccaly AJ; Kovalenko P; Parrino J; Boyapati A; Xu C; van Hoogstraten H; Ishii T; Davis JD; DiCioccio AT
    J Clin Pharmacol; 2021 Jan; 61(1):90-104. PubMed ID: 32726514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study).
    Kennedy WP; Simon JA; Offutt C; Horn P; Herman A; Townsend MJ; Tang MT; Grogan JL; Hsieh F; Davis JC
    Arthritis Res Ther; 2014 Oct; 16(5):467. PubMed ID: 25359150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease.
    Li C; Shoji S; Beebe J
    Br J Clin Pharmacol; 2018 Sep; 84(9):2059-2074. PubMed ID: 29776017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local versus systemic anti-tumour necrosis factor-α effects of adalimumab in rheumatoid arthritis: pharmacokinetic modelling analysis of interaction between a soluble target and a drug.
    Stepensky D
    Clin Pharmacokinet; 2012 Jul; 51(7):443-55. PubMed ID: 22540283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.
    Bastida C; Ruiz-Esquide V; Pascal M; de Vries Schultink AHM; Yagüe J; Sanmartí R; Huitema ADR; Soy D
    Br J Clin Pharmacol; 2018 Apr; 84(4):716-725. PubMed ID: 29314183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial.
    Goss SL; Klein CE; Jin Z; Locke CS; Rodila RC; Kupper H; Burmester GR; Awni WM
    Clin Ther; 2018 Feb; 40(2):309-319. PubMed ID: 29402521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of etanercept dose reduction in patients with rheumatoid arthritis using pharmacokinetic/pharmacodynamic modeling and simulation.
    Hsu LF; Huang JD
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):776-86. PubMed ID: 24887337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure-response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components.
    Bastida C; Soy D; Ruiz-Esquide V; Sanmartí R; Huitema ADR
    Br J Clin Pharmacol; 2019 Aug; 85(8):1710-1718. PubMed ID: 30958574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA.
    Abdallah H; Hsu JC; Lu P; Fettner S; Zhang X; Douglass W; Bao M; Rowell L; Burmester GR; Kivitz A
    J Clin Pharmacol; 2017 Apr; 57(4):459-468. PubMed ID: 27599663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus.
    Cohen S; Clowse M; Pardo P; Bhattacharya I; Menon S; Gourley I; Diehl A
    Clin Ther; 2016 Jun; 38(6):1417-1434.e2. PubMed ID: 27112532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study.
    Haraoui B; Cividino A; Stewart J; Guérette B; Keystone EC
    BMC Musculoskelet Disord; 2011 Nov; 12():261. PubMed ID: 22093579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
    Taylor PC; Saurigny D; Vencovsky J; Takeuchi T; Nakamura T; Matsievskaia G; Hunt B; Wagner T; Souberbielle B;
    Arthritis Res Ther; 2019 Apr; 21(1):101. PubMed ID: 30999929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.
    Jani RH; Gupta R; Bhatia G; Rathi G; Ashok Kumar P; Sharma R; Kumar U; Gauri LA; Jadhav P; Bartakke G; Haridas V; Jain D; Mendiratta SK
    Int J Rheum Dis; 2016 Nov; 19(11):1157-1168. PubMed ID: 26176644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data.
    Nassar-Sheikh Rashid A; Hooijberg F; Bergkamp SC; Gruppen MP; Kuijpers TW; Nurmohamed M; Rispens T; Wolbink G; van den Berg JM; Schonenberg-Meinema D; Mathôt RAA
    Paediatr Drugs; 2024 Jul; 26(4):441-450. PubMed ID: 38630199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From synovial tissue to peripheral blood: myeloid related protein 8/14 is a sensitive biomarker for effective treatment in early drug development in patients with rheumatoid arthritis.
    Choi IY; Gerlag DM; Holzinger D; Roth J; Tak PP
    PLoS One; 2014; 9(8):e106253. PubMed ID: 25166859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetic-Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28-Joint C-Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis.
    Ma L; Xu C; Paccaly A; Kanamaluru V
    Clin Pharmacokinet; 2020 Nov; 59(11):1451-1466. PubMed ID: 32451909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure-response modeling of peficitinib efficacy in patients with rheumatoid arthritis.
    Toyoshima J; Kaibara A; Shibata M; Kaneko Y; Izutsu H; Nishimura T
    Pharmacol Res Perspect; 2021 May; 9(3):e00744. PubMed ID: 33929089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.